Timeline
Nuformix
Nuformix reports positive preclinical data for IPF drug candidate
Nuformix results highlight progress as it advances 'viable and attractive' candidates
More in Pharma
Shield Therapeutics takes full US control of ACCRUFeR
The iron deficiency specialist will absorb its co-commercialisation partner's sales force and retain all US gross profit from ACCRUFeR, paying Viatris a royalty instead of a profit share.